A9950
Aniracetam
≥98%
Synonym(s):
1-(4-Methoxybenzoyl)-2-pyrrolidinone, Ro 13-5057
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C12H13NO3
CAS Number:
Molecular Weight:
219.24
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
assay
≥98%
originator
Roche
SMILES string
COc1ccc(cc1)C(=O)N2CCCC2=O
InChI
1S/C12H13NO3/c1-16-10-6-4-9(5-7-10)12(15)13-8-2-3-11(13)14/h4-7H,2-3,8H2,1H3
InChI key
ZXNRTKGTQJPIJK-UHFFFAOYSA-N
Gene Information
human ... GRM1(2911), GRM2(2912), GRM3(2913), GRM4(2914), GRM5(2915), GRM6(2916), GRM7(2917), GRM8(2918)
rat ... Gria1(50592)
Application
Aniracetam has been used in the inhibition screening assays for kinase enzyme.
Biochem/physiol Actions
Aniracetam is a piracetam analog and has low bioavailability due to rapid excretion. It enhances the cognitive thinking and is effective for treatment of sleep and behavioral disorders. Aniracetam is prescribed for anxiety and also enhances learning and memory in situations with induced damage of the brain.
Cognition enhancer (nootropic) that potentiates AMPA receptor mediated ion conductance and potentiates metabotropic glutamate receptor activity.
Features and Benefits
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Storage Class
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Kazuo Nakamura
CNS drug reviews, 8(1), 70-89 (2002-06-19)
Aniracetam is a pyrrolidinone-type cognition enhancer that has been clinically used in the treatment of behavioral and psychological symptoms of dementia following stroke and in Alzheimer's disease. New discoveries in the behavioral pharmacology, biochemistry and pharmacokinetics of aniracetam provided new
A Pittaluga et al.
Naunyn-Schmiedeberg's archives of pharmacology, 359(4), 272-279 (1999-05-27)
Aniracetam, 1-(1,3-benzodioxol-5-yl-carbonyl)piperidine (1-BCP) and cyclothiazide, three compounds considered to enhance cognition through modulation of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors, were evaluated in the 'kynurenate test', a biochemical assay in which some nootropics have been shown to prevent the antagonism by kynurenic
Chrysi C Koliaki et al.
CNS neuroscience & therapeutics, 18(4), 302-312 (2011-11-11)
Dementia constitutes an increasingly prevalent cognitive disorder with serious socioeconomic implications. In the present study, we aimed to evaluate the efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors (ChEIs), in terms of several neuropsychological parameters, in a
Rudolf Mueller et al.
Bioorganic & medicinal chemistry letters, 21(13), 3923-3926 (2011-06-04)
AMPA receptors (AMPARs) are an increasingly important therapeutic target in the CNS. Aniracetam, the first identified potentiator of AMPARs, led to the rigid and more potent CX614. This lead molecule was optimized in order to increase affinity towards the AMPA
A C Arai et al.
Current drug targets, 8(5), 583-602 (2007-05-17)
Ampakines are drugs structurally derived from aniracetam that potentiate currents mediated by AMPA type glutamate receptors. These drugs slow deactivation and attenuate desensitization of AMPA receptor currents, increase synaptic responses and enhance long-term potentiation. This review focuses mainly on recent
Related Content
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service